Medulloblastoma - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：57頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Medulloblastoma - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Medulloblastoma - Pipeline Review, H1 2014’, provides an overview of the Medulloblastoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Medulloblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Medulloblastoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Medulloblastoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Medulloblastoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Medulloblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Medulloblastoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Medulloblastoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Medulloblastoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Medulloblastoma - Pipeline Review, H1 2014’, provides an overview of the Medulloblastoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Medulloblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Medulloblastoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Medulloblastoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Medulloblastoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Medulloblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Medulloblastoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Medulloblastoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Medulloblastoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Medulloblastoma Overview 7
Therapeutics Development 8
Pipeline Products for Medulloblastoma - Overview 8
Pipeline Products for Medulloblastoma - Comparative Analysis 9
Medulloblastoma - Therapeutics under Development by Companies 10
Medulloblastoma - Therapeutics under Investigation by Universities/Institutes 12
Medulloblastoma - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Medulloblastoma - Products under Development by Companies 17
Medulloblastoma - Products under Investigation by Universities/Institutes 18
Medulloblastoma - Companies Involved in Therapeutics Development 19
Takeda Pharmaceutical Company Limited 19
Novartis AG 20
Lixte Biotechnology Holdings, Inc. 21
ThromboGenics NV 22
Stemline Therapeutics, Inc. 23
Archer Biosciences, Inc 24
Conkwest, Inc. 25
TheraBiologics, Inc. 26
Medulloblastoma - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
erismodegib - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ARC-100 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
erismodegib - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
TB-403 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
SL-301 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
CST-102 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
TBX-02 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Siomycin A - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
LB-102 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Medulloblastoma - Recent Pipeline Updates 51
Medulloblastoma - Dormant Projects 53
Medulloblastoma - Product Development Milestones 54
Featured News & Press Releases 54
Feb 28, 2013: ThromboGenics And BioInvent Announce Publication Of Scientific Data On TB-403 In Journal Cell 54
Sep 19, 2011: Researchers Discover Regulatory Protein As Potential Drug Target For Brain Tumors 54
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 57
Disclaimer 57
List of Tables
Number of Products under Development for Medulloblastoma, H1 2014 8
Number of Products under Development for Medulloblastoma - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Comparative Analysis by Unknown Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Medulloblastoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 19
Medulloblastoma - Pipeline by Novartis AG, H1 2014 20
Medulloblastoma - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2014 21
Medulloblastoma - Pipeline by ThromboGenics NV, H1 2014 22
Medulloblastoma - Pipeline by Stemline Therapeutics, Inc., H1 2014 23
Medulloblastoma - Pipeline by Archer Biosciences, Inc, H1 2014 24
Medulloblastoma - Pipeline by Conkwest, Inc., H1 2014 25
Medulloblastoma - Pipeline by TheraBiologics, Inc., H1 2014 26
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Stage and Target, H1 2014 29
Number of Products by Stage and Mechanism of Action, H1 2014 31
Number of Products by Stage and Route of Administration, H1 2014 33
Number of Products by Stage and Molecule Type, H1 2014 35
Medulloblastoma Therapeutics - Recent Pipeline Updates, H1 2014 51
Medulloblastoma - Dormant Projects, H1 2014 53
List of Figures
Number of Products under Development for Medulloblastoma, H1 2014 8
Number of Products under Development for Medulloblastoma - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Top 10 Target, H1 2014 28
Number of Products by Stage and Top 10 Target, H1 2014 29
Number of Products by Top 10 Mechanism of Action, H1 2014 30
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 31
Number of Products by Top 10 Route of Administration, H1 2014 32
Number of Products by Stage and Top 10 Route of Administration, H1 2014 33
Number of Products by Top 10 Molecule Type, H1 2014 34
Number of Products by Stage and Top 10 Molecule Type, H1 2014 35
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Medulloblastoma Overview 7
Therapeutics Development 8
Pipeline Products for Medulloblastoma - Overview 8
Pipeline Products for Medulloblastoma - Comparative Analysis 9
Medulloblastoma - Therapeutics under Development by Companies 10
Medulloblastoma - Therapeutics under Investigation by Universities/Institutes 12
Medulloblastoma - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Medulloblastoma - Products under Development by Companies 17
Medulloblastoma - Products under Investigation by Universities/Institutes 18
Medulloblastoma - Companies Involved in Therapeutics Development 19
Takeda Pharmaceutical Company Limited 19
Novartis AG 20
Lixte Biotechnology Holdings, Inc. 21
ThromboGenics NV 22
Stemline Therapeutics, Inc. 23
Archer Biosciences, Inc 24
Conkwest, Inc. 25
TheraBiologics, Inc. 26
Medulloblastoma - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
erismodegib - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ARC-100 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
erismodegib - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
TB-403 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
SL-301 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
CST-102 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
TBX-02 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Siomycin A - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
LB-102 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Medulloblastoma - Recent Pipeline Updates 51
Medulloblastoma - Dormant Projects 53
Medulloblastoma - Product Development Milestones 54
Featured News & Press Releases 54
Feb 28, 2013: ThromboGenics And BioInvent Announce Publication Of Scientific Data On TB-403 In Journal Cell 54
Sep 19, 2011: Researchers Discover Regulatory Protein As Potential Drug Target For Brain Tumors 54
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 57
Disclaimer 57
List of Tables
Number of Products under Development for Medulloblastoma, H1 2014 8
Number of Products under Development for Medulloblastoma - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Comparative Analysis by Unknown Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Medulloblastoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 19
Medulloblastoma - Pipeline by Novartis AG, H1 2014 20
Medulloblastoma - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2014 21
Medulloblastoma - Pipeline by ThromboGenics NV, H1 2014 22
Medulloblastoma - Pipeline by Stemline Therapeutics, Inc., H1 2014 23
Medulloblastoma - Pipeline by Archer Biosciences, Inc, H1 2014 24
Medulloblastoma - Pipeline by Conkwest, Inc., H1 2014 25
Medulloblastoma - Pipeline by TheraBiologics, Inc., H1 2014 26
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Stage and Target, H1 2014 29
Number of Products by Stage and Mechanism of Action, H1 2014 31
Number of Products by Stage and Route of Administration, H1 2014 33
Number of Products by Stage and Molecule Type, H1 2014 35
Medulloblastoma Therapeutics - Recent Pipeline Updates, H1 2014 51
Medulloblastoma - Dormant Projects, H1 2014 53
List of Figures
Number of Products under Development for Medulloblastoma, H1 2014 8
Number of Products under Development for Medulloblastoma - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Top 10 Target, H1 2014 28
Number of Products by Stage and Top 10 Target, H1 2014 29
Number of Products by Top 10 Mechanism of Action, H1 2014 30
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 31
Number of Products by Top 10 Route of Administration, H1 2014 32
Number of Products by Stage and Top 10 Route of Administration, H1 2014 33
Number of Products by Top 10 Molecule Type, H1 2014 34
Number of Products by Stage and Top 10 Molecule Type, H1 2014 35
